Anti-EGFR domain III (Nimotuzumab), Human IgG1, kappa Antibody

Anti-EGFR domain III (Nimotuzumab), Human IgG1, kappa Antibodyis available at Gentaur for Next week Delivery.

Description: Recombinant monoclonal antibody to EGFR domain III. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody h-R3 (Nimotuzumab). This antibody binds to human EGFR and inhibits EGF-dependent clonogenic growth of NRK cells and completely blocks EGF stimulated autophosphorylation of the receptor

Immunogen Sequence:Antibody generated by humanization of the murine antibody R3, raised against EGFR purified from placenta membranes and A431 tumors

Target Alternative Name:ERBB; ERBB1; HER1; PIG61; mENA; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; epidermal growth factor, Nimotuzumab

Species Reactivities:Human

Tag Line:Protein A affinity purified recombinant monoclonal antibody to detect EGFR domain III expression in humans

Formulation:Supplied in PBS, pH 7.5

Purification: SOURCE: CHO cells

Application:Immunohistochemistry (IHC), Immunofluorescence (IF), Block, Flow Cytometry

Positive Control:/

Application And Usages:Block, FC, IHC

Handling:The antibody solution should be gently mixed before use.